{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Antipsychotic+Therapy&page=2",
    "query": {
      "intervention": "Standard Antipsychotic Therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Antipsychotic+Therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Antipsychotic+Therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T22:07:29.430Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00616798",
      "title": "A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "RO4917838",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard antipsychotic therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 323,
      "start_date": "2008-03",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2014-06-24",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 14,
      "location_summary": "Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more",
      "locations": [
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616798"
    },
    {
      "nct_id": "NCT02034253",
      "title": "Glutamate, Brain Connectivity and Duration of Untreated Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Psychosis",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "17 Years to 35 Years"
      },
      "enrollment_count": 134,
      "start_date": "2014-01",
      "completion_date": "2018-11",
      "has_results": false,
      "last_update_posted_date": "2019-01-22",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02034253"
    },
    {
      "nct_id": "NCT02237417",
      "title": "Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Standard of Care Oral antipsychotics",
          "type": "DRUG"
        },
        {
          "name": "IM aripiprazole once monthly",
          "type": "DRUG"
        },
        {
          "name": "No Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-09-01",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237417"
    },
    {
      "nct_id": "NCT07130500",
      "title": "Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia Disorder",
        "Schizoaffective Disorder",
        "Bipolar Disorder (BD)",
        "Substance Use Disorder (SUD)"
      ],
      "interventions": [
        {
          "name": "Financial incentives for adherence to long-acting injectable medication",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of care with monthly surveys",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2026-03-09",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 5,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07130500"
    },
    {
      "nct_id": "NCT05542264",
      "title": "A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SEP-363856",
          "type": "DRUG"
        },
        {
          "name": "Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2022-11-15",
      "completion_date": "2024-02-12",
      "has_results": false,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05542264"
    },
    {
      "nct_id": "NCT00538122",
      "title": "Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "24 Holter Monitor Recording",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-07",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538122"
    },
    {
      "nct_id": "NCT06245213",
      "title": "A Study of ANAVEX3-71 in Adults With Schizophrenia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ANAVEX3-71 oral capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anavex Life Sciences Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 71,
      "start_date": "2024-03-15",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 1,
      "location_summary": "Marlton, New Jersey",
      "locations": [
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06245213"
    },
    {
      "nct_id": "NCT02440594",
      "title": "The PACE/PACENET Behavioral Health Laboratory Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Enhanced BHL Program Services",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard BHL Program Services",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2432,
      "start_date": "2010-08",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-07",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02440594"
    },
    {
      "nct_id": "NCT06333990",
      "title": "Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mild Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Quetiapine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "TAU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foundation for Advancing Veterans' Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 146,
      "start_date": "2024-07-09",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 2,
      "location_summary": "Albuquerque, New Mexico • San Antonio, Texas",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333990"
    },
    {
      "nct_id": "NCT06482554",
      "title": "Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Apathy",
        "Schizophrenia",
        "Schizophrenia; Psychosis"
      ],
      "interventions": [
        {
          "name": "Lumateperone 42 mg",
          "type": "DRUG"
        },
        {
          "name": "Risperidone 2 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center Shreveport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-04T22:07:29.430Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06482554"
    }
  ]
}